Market Performance
Sudarshan Pharma Industries’ share price gained more than 4% intraday on Monday, touching a high of ₹32.50 on the BSE.
- Previous close: ₹31.06
- Opening price: ₹31.50
- Intraday high: ₹32.50 (+4%)
The stock has been trading under the ₹50 mark, attracting retail investor interest after its latest quarterly results and business updates.
Q1 Results 2025
For the quarter ending June 2025 (Q1FY26), Sudarshan Pharma Industries reported:
- Revenue: ₹142.31 crore (↑40% YoY from ₹101.73 crore)
- Net Profit: ₹3.74 crore (vs. loss of ₹1.18 crore in Q1FY25)
- Sequentially, profit declined from ₹7.03 crore in Jan–Mar 2025, which had included exceptional gains of ₹1.65 crore.
- Revenue also dipped slightly from ₹161.57 crore in the previous quarter.
Acquisition Update
Alongside its earnings, Sudarshan Pharma announced an asset acquisition from Srigen Lifesciences Private Limited in Telangana.
Key details of the acquisition:
- Total cost: ₹25.50 crore
- Assets include land, buildings, plant & machinery covering 1,563.15 sq. meters
- Facility has 80-kiloliter reactor capacity
- Includes 50 potential API key starting materials with viable commercial technology
- Some materials are already patented and being manufactured at a commercial scale with proper regulatory support
Share Price Movement
Sudarshan Pharma Industries’ stock under ₹50 drew investor attention with strong volumes.
- Opened at ₹31.50 (↑1% from previous close)
- Rose to ₹32.50 intraday, marking a 4% gain
- Strong momentum followed its Q1 results and expansion updates
Summary
The Pharma stock under ₹50 — Sudarshan Pharma Industries — gained over 4% intraday after posting a ₹3.74 crore net profit in Q1 2025 and announcing a ₹25.50 crore acquisition in Telangana. With revenue up 40% YoY and new manufacturing assets added, the company is expanding its footprint in the pharma sector.
Easy & quick